Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

471
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
471
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

397
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
397
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

423
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
423

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Explainable, Generative and Agentic Artificial Intelligence for the Peripheral Blood Film.

International journal of laboratory hematology·2026
Same author

Photo Quiz: A "tail" of spiraling deception.

Journal of clinical microbiology·2026
Same author

Thrombosis in Neuromuscular Medicine: Current Evidence, Unmet Needs, and Future Directions.

Journal of clinical medicine·2026
Same author

C-reactive protein and risk of venous thromboembolism - results from the MEGA study.

Thrombosis research·2026
Same author

RDW-to-albumin ratio correlates with serum neurofilament light chain.

Annals of the Academy of Medicine, Singapore·2026
Same author

Machine Learning Models for Predicting Bleeding Risk in Anticoagulated Patients with Atrial Fibrillation and Venous Thromboembolism: A Comparative Evidence Synthesis.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Apr 15, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K

Anticoagulation Stewardship Program in the DOAC Era.

Jian Xiong Ng1, Su Ching Tan1, Pei Lin Koh2,3

  • 1Department of Pharmacy, National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074, Singapore.

Journal of Clinical Medicine
|April 14, 2026
PubMed
Summary

The withdrawal of andexanet alfa necessitates new strategies for direct oral anticoagulant reversal. Prothrombin complex concentrates (PCCs) are now key for Factor Xa inhibitors, alongside stewardship programs.

Keywords:
activated prothrombin complex concentrateandexanet alfaanticoagulation reversalbleeding managementdirect oral anticoagulantsidarucizumabprothrombin complex concentratestewardship program

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.8K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.4K

Related Experiment Videos

Last Updated: Apr 15, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.8K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.4K

Area of Science:

  • Pharmacology and Therapeutics
  • Hematology
  • Clinical Pharmacy

Background:

  • Direct oral anticoagulants (DOACs) offer significant antithrombotic benefits but pose bleeding risks requiring effective reversal agents.
  • Recent regulatory actions, including the U.S. market withdrawal of andexanet alfa, have critically impacted DOAC reversal strategies.
  • Anticoagulation stewardship programs (ASPs) are vital for managing DOACs and their reversal in the evolving clinical landscape.

Purpose of the Study:

  • To review the current landscape of DOAC reversal agents and strategies.
  • To analyze the impact of regulatory changes, specifically the andexanet alfa withdrawal, on clinical practice.
  • To provide guidance for anticoagulation stewardship programs in optimizing DOAC reversal.

Main Methods:

  • A narrative review synthesizing data from key clinical trials (RE-VERSE AD, ANNEXA-4, ANNEXA-I).
  • Inclusion of current clinical guidelines and emerging research on reversal agents.
  • Critical analysis of regulatory updates, including the FDA's withdrawal of andexanet alfa.

Main Results:

  • Idarucizumab remains the sole FDA-approved specific antidote for dabigatran.
  • Following andexanet alfa's withdrawal, 4-factor and activated prothrombin complex concentrates (PCCs) are primary reversal agents for Factor Xa inhibitors, showing comparable efficacy.
  • Ciraparantag, a universal reversal agent, is in Phase III development, offering future potential.

Conclusions:

  • The departure of andexanet alfa has fundamentally altered DOAC reversal protocols.
  • Optimizing PCC-based strategies and enhancing ASPs are crucial for managing DOAC-associated bleeding.
  • Institutions must update algorithms, ensure PCC availability, and prepare for novel universal antidotes.